S&P 500   4,287.37 (-0.29%)
DOW   33,505.71 (-0.48%)
QQQ   357.89 (-0.03%)
AAPL   171.04 (+0.21%)
MSFT   315.62 (+0.63%)
META   302.19 (-0.58%)
GOOGL   131.29 (-0.77%)
AMZN   126.61 (+0.50%)
TSLA   249.03 (+1.08%)
NVDA   434.99 (+0.95%)
NIO   8.97 (+0.67%)
BABA   86.83 (+1.51%)
AMD   103.23 (+0.46%)
T   14.95 (-0.40%)
F   12.43 (-1.04%)
MU   67.60 (+3.68%)
CGC   0.78 (-3.80%)
GE   110.12 (-1.98%)
DIS   80.58 (+0.56%)
AMC   8.00 (+2.70%)
PFE   33.06 (+3.02%)
PYPL   58.21 (+0.05%)
NFLX   376.29 (-0.02%)
S&P 500   4,287.37 (-0.29%)
DOW   33,505.71 (-0.48%)
QQQ   357.89 (-0.03%)
AAPL   171.04 (+0.21%)
MSFT   315.62 (+0.63%)
META   302.19 (-0.58%)
GOOGL   131.29 (-0.77%)
AMZN   126.61 (+0.50%)
TSLA   249.03 (+1.08%)
NVDA   434.99 (+0.95%)
NIO   8.97 (+0.67%)
BABA   86.83 (+1.51%)
AMD   103.23 (+0.46%)
T   14.95 (-0.40%)
F   12.43 (-1.04%)
MU   67.60 (+3.68%)
CGC   0.78 (-3.80%)
GE   110.12 (-1.98%)
DIS   80.58 (+0.56%)
AMC   8.00 (+2.70%)
PFE   33.06 (+3.02%)
PYPL   58.21 (+0.05%)
NFLX   376.29 (-0.02%)
S&P 500   4,287.37 (-0.29%)
DOW   33,505.71 (-0.48%)
QQQ   357.89 (-0.03%)
AAPL   171.04 (+0.21%)
MSFT   315.62 (+0.63%)
META   302.19 (-0.58%)
GOOGL   131.29 (-0.77%)
AMZN   126.61 (+0.50%)
TSLA   249.03 (+1.08%)
NVDA   434.99 (+0.95%)
NIO   8.97 (+0.67%)
BABA   86.83 (+1.51%)
AMD   103.23 (+0.46%)
T   14.95 (-0.40%)
F   12.43 (-1.04%)
MU   67.60 (+3.68%)
CGC   0.78 (-3.80%)
GE   110.12 (-1.98%)
DIS   80.58 (+0.56%)
AMC   8.00 (+2.70%)
PFE   33.06 (+3.02%)
PYPL   58.21 (+0.05%)
NFLX   376.29 (-0.02%)
S&P 500   4,287.37 (-0.29%)
DOW   33,505.71 (-0.48%)
QQQ   357.89 (-0.03%)
AAPL   171.04 (+0.21%)
MSFT   315.62 (+0.63%)
META   302.19 (-0.58%)
GOOGL   131.29 (-0.77%)
AMZN   126.61 (+0.50%)
TSLA   249.03 (+1.08%)
NVDA   434.99 (+0.95%)
NIO   8.97 (+0.67%)
BABA   86.83 (+1.51%)
AMD   103.23 (+0.46%)
T   14.95 (-0.40%)
F   12.43 (-1.04%)
MU   67.60 (+3.68%)
CGC   0.78 (-3.80%)
GE   110.12 (-1.98%)
DIS   80.58 (+0.56%)
AMC   8.00 (+2.70%)
PFE   33.06 (+3.02%)
PYPL   58.21 (+0.05%)
NFLX   376.29 (-0.02%)
NASDAQ:GBIO

Generation Bio (GBIO) Stock Forecast, Price & News

$3.76
-0.01 (-0.27%)
(As of 01:21 PM ET)
Compare
Today's Range
$3.73
$4.07
50-Day Range
$3.65
$5.36
52-Week Range
$3.15
$7.35
Volume
13,362 shs
Average Volume
266,222 shs
Market Capitalization
$247.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.05

Generation Bio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
139.3% Upside
$9.05 Price Target
Short Interest
Bearish
4.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Generation Bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$31,846 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.05) to ($1.75) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

299th out of 970 stocks

Biotechnology Industry

2nd out of 14 stocks


GBIO stock logo

About Generation Bio (NASDAQ:GBIO) Stock

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

GBIO Price History

GBIO Stock News Headlines

This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
JMP Securities Sticks to Its Buy Rating for Generation Bio (GBIO)
JMP Securities Keeps Their Buy Rating on Generation Bio (GBIO)
Where Generation Bio Stands With Analysts
The Latest Analyst Ratings for Generation Bio
Needham Remains a Buy on Generation Bio (GBIO)
See More Headlines
Receive GBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Generation Bio and its competitors with MarketBeat's FREE daily newsletter.

GBIO Company Calendar

Last Earnings
8/02/2023
Today
9/29/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GBIO
Fax
N/A
Employees
150
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.05
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$2.23
Forecasted Upside/Downside
+139.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-136,640,000.00
Pretax Margin
-14,417.16%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.75 per share

Miscellaneous

Free Float
52,216,000
Market Cap
$249.22 million
Optionable
Not Optionable
Beta
2.22
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Cameron Geoffrey McDonough M.D. (Age 53)
    Pres, CEO & Director
    Comp: $939.09k
  • Dr. Matthew Norkunas M.B.A. (Age 45)
    M.D., Chief Financial Officer
    Comp: $611.11k
  • Dr. Matthew Stanton Ph.D. (Age 50)
    Chief Scientific Officer
    Comp: $654.83k
  • Dr. Douglas Kerr M.B.A. (Age 56)
    M.D., Ph.D., Chief Medical Officer
    Comp: $659.1k
  • Dr. Tracy Zimmermann Ph.D. (Age 53)
    Chief Devel. Officer
    Comp: $622.74k
  • Dr. Mark D. Angelino Ph.D. (Age 50)
    Co-Founder
  • Dr. Robert Kotin Ph.D. (Age 67)
    Co-Founder
  • Ms. Antoinette Paone M.B.A. (Age 45)
    M.S., Chief Operating Officer
  • Ms. Yalonda Howze J.D. (Age 51)
    Chief Legal Officer & Sec.
  • Ms. Jasmin Tower
    Sr. VP of People & Operations













GBIO Stock - Frequently Asked Questions

Should I buy or sell Generation Bio stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Generation Bio in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GBIO shares.
View GBIO analyst ratings
or view top-rated stocks.

What is Generation Bio's stock price forecast for 2023?

6 Wall Street analysts have issued 1-year price targets for Generation Bio's shares. Their GBIO share price forecasts range from $2.23 to $14.00. On average, they predict the company's stock price to reach $9.05 in the next twelve months. This suggests a possible upside of 139.3% from the stock's current price.
View analysts price targets for GBIO
or view top-rated stocks among Wall Street analysts.

How have GBIO shares performed in 2023?

Generation Bio's stock was trading at $3.93 on January 1st, 2023. Since then, GBIO shares have decreased by 3.8% and is now trading at $3.78.
View the best growth stocks for 2023 here
.

When is Generation Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our GBIO earnings forecast
.

How were Generation Bio's earnings last quarter?

Generation Bio Co. (NASDAQ:GBIO) announced its earnings results on Wednesday, August, 2nd. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. The business earned $0.88 million during the quarter, compared to analyst estimates of $7.50 million.

What other stocks do shareholders of Generation Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Generation Bio investors own include DocuSign (DOCU), NVIDIA (NVDA), Overstock.com (OSTK), Boeing (BA), Pure Storage (PSTG), Mastercard (MA), QUALCOMM (QCOM), Riot Platforms (RIOT), Twilio (TWLO) and Enphase Energy (ENPH).

When did Generation Bio IPO?

(GBIO) raised $126 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Generation Bio's stock symbol?

Generation Bio trades on the NASDAQ under the ticker symbol "GBIO."

How do I buy shares of Generation Bio?

Shares of GBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Generation Bio's stock price today?

One share of GBIO stock can currently be purchased for approximately $3.78.

How much money does Generation Bio make?

Generation Bio (NASDAQ:GBIO) has a market capitalization of $249.22 million. The company earns $-136,640,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis.

How many employees does Generation Bio have?

The company employs 150 workers across the globe.

How can I contact Generation Bio?

Generation Bio's mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is generationbio.com. The company can be reached via phone at 617-655-7500 or via email at investors@generationbio.com.

This page (NASDAQ:GBIO) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -